secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0000950170-23-019141
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HCW Biologics Q1 net loss $5.1M, revenue $42K; enters $26.25M credit line
-------------------------------------------------------------------------

- Net loss of $5.1M vs $2.1M in Q1 2022; revenue dropped to $42K from $3.1M.
- R&D expenses up 26% to $2.3M; G&A up 66% to $3.1M partly due to Altor litigation.
- Entered $26.25M development line of credit (7% fixed, 5-yr, interest-only) for facility buildout.
- Altor/NantCell litigation moved to arbitration; no loss accrual recorded.
- Cash runway extended into 2025 via the credit line and existing cash.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000095017023019141/0000950170-23-019141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000095017023019141/hcwb-20230509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-019141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer